BACKGROUND: Hypophosphatasia (HPP) is a rare genetic disorder resulting in variable alterations of bone formation and mineralization that are caused by mutations in the ALPL gene, encoding the tissue-nonspecific alkaline phosphatase (ALP) enzyme. METHODS: In this phase IIA open-label, single-center, intra-patient, dose-escalating study, adult patients with HPP received 3 ascending intravenous doses of 5, 10, and 20 mg/kg BPS804, a fully human anti-sclerostin monoclonal antibody, on days 1, 15, and 29, respectively. Patients were followed for 16 weeks after the last dose. We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy, and safety of BPS804 administrations at specified intervals during treatment and follow-up. RESULTS: Eight patients (mean age 47.8 years) were enrolled in the study (6 females, 2 males). BPS804 treatment increased mean ALP and bone-specific ALP enzymatic activity between days 2 and 29. Transient increases in the bone formation markers procollagen type-I N-terminal propeptide (PINP), osteocalcin, and parathyroid hormone as well as a transient decrease in the bone resorption marker C-telopeptide of type I collagen (CTX-1) were observed. Lumbar spine bone mineral density showed a mean increase by day 85 and at end of study. Treatment-associated adverse events were mild and transient. CONCLUSION: BPS804 treatment was well tolerated and resulted in increases in bone formation biomarkers and bone mineral density, suggesting that sclerostin inhibition could be applied to enhance bone mineral density, stability, and regeneration in non-life-threatening clinical situations in adults with HPP. TRIAL REGISTRATION: Clinicaltrials.gov NCT01406977. FUNDING: Novartis Institutes for BioMedical Research, Basel, Switzerland.
BACKGROUND:Hypophosphatasia (HPP) is a rare genetic disorder resulting in variable alterations of bone formation and mineralization that are caused by mutations in the ALPL gene, encoding the tissue-nonspecific alkaline phosphatase (ALP) enzyme. METHODS: In this phase IIA open-label, single-center, intra-patient, dose-escalating study, adult patients with HPP received 3 ascending intravenous doses of 5, 10, and 20 mg/kg BPS804, a fully human anti-sclerostin monoclonal antibody, on days 1, 15, and 29, respectively. Patients were followed for 16 weeks after the last dose. We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy, and safety of BPS804 administrations at specified intervals during treatment and follow-up. RESULTS: Eight patients (mean age 47.8 years) were enrolled in the study (6 females, 2 males). BPS804 treatment increased mean ALP and bone-specific ALP enzymatic activity between days 2 and 29. Transient increases in the bone formation markers procollagen type-I N-terminal propeptide (PINP), osteocalcin, and parathyroid hormone as well as a transient decrease in the bone resorption marker C-telopeptide of type I collagen (CTX-1) were observed. Lumbar spine bone mineral density showed a mean increase by day 85 and at end of study. Treatment-associated adverse events were mild and transient. CONCLUSION:BPS804 treatment was well tolerated and resulted in increases in bone formation biomarkers and bone mineral density, suggesting that sclerostin inhibition could be applied to enhance bone mineral density, stability, and regeneration in non-life-threatening clinical situations in adults with HPP. TRIAL REGISTRATION: Clinicaltrials.gov NCT01406977. FUNDING: Novartis Institutes for BioMedical Research, Basel, Switzerland.
Authors: Isabel R Orriss; Michelle L Key; Andrea Brandao-Burch; Jessal J Patel; Geoffrey Burnstock; Timothy R Arnett Journal: Bone Date: 2012-06-26 Impact factor: 4.398
Authors: F Barvencik; F Timo Beil; M Gebauer; B Busse; T Koehne; S Seitz; J Zustin; P Pogoda; T Schinke; M Amling Journal: Osteoporos Int Date: 2011-01-26 Impact factor: 4.507
Authors: H L Müller; M Yamazaki; T Michigami; T Kageyama; E Schönau; P Schneider; K Ozono Journal: J Clin Endocrinol Metab Date: 2000-02 Impact factor: 5.958
Authors: Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty Journal: J Bone Miner Res Date: 2009-04 Impact factor: 6.741
Authors: L López-Delgado; L Riancho-Zarrabeitia; M T García-Unzueta; J A Tenorio; M García-Hoyos; P Lapunzina; C Valero; J A Riancho Journal: Osteoporos Int Date: 2018-06-12 Impact factor: 4.507
Authors: Bei Li; Xiaoning He; Zhiwei Dong; Kun Xuan; Wei Sun; Li Gao; Shiyu Liu; Wenjia Liu; Chenghu Hu; Yimin Zhao; Songtao Shi; Yan Jin Journal: Bone Res Date: 2020-04-26 Impact factor: 13.567
Authors: Sebastian Simon; Heinrich Resch; Klaus Klaushofer; Paul Roschger; Jochen Zwerina; Roland Kocijan Journal: Curr Rheumatol Rep Date: 2018-09-10 Impact factor: 4.592
Authors: Jonas Bovijn; Kristi Krebs; Chia-Yen Chen; Ruth Boxall; Jenny C Censin; Teresa Ferreira; Sara L Pulit; Craig A Glastonbury; Samantha Laber; Iona Y Millwood; Kuang Lin; Liming Li; Zhengming Chen; Lili Milani; George Davey Smith; Robin G Walters; Reedik Mägi; Benjamin M Neale; Cecilia M Lindgren; Michael V Holmes Journal: Sci Transl Med Date: 2020-06-24 Impact factor: 17.956